Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

The search for effective Alzheimer’s treatments is emerging as a promising market, capturing the attention of major ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Alzheimer's disease is the most common type of dementia. Here, we break down what to know about this disease, including: What ...

Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.

A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly treatment at home in 15 seconds ... Mild ...

Mild chronic small vessel disease, or cerebral small vessel disease (CSVD), is an umbrella term for a range of conditions ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...